Biohaven Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Biohaven non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-13.6%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-13.6%
Rendimento futuro dei dividendi	0%
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

May 18

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Apr 06

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Mar 01

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Feb 28

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Dec 08

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Dec 04

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Sep 27

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Aug 28

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Jul 22

Biohaven: A Promising Investment In Innovative Neurological Therapies

Jun 14

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Jun 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Apr 06

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

Feb 21

Biohaven Ltd: Assessing The Spinoff

Dec 07

Biohaven Non-GAAP EPS of -$1.25

Nov 09

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di BHVN siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di BHVN siano aumentati.

Rendimento dei dividendi rispetto al mercato

Biohaven Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di BHVN rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (BHVN)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Biotechs)	2.3%
Analista previsionale (BHVN) (fino a 3 anni)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di BHVN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di BHVN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di BHVN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché BHVN non ha segnalato alcun pagamento.

Biohaven Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

New major risk - Financial position

Biohaven: A Complicated Tale

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Price target increased by 9.2% to US$62.36

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Consensus EPS estimates fall by 21%

New major risk - Financial position

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

New minor risk - Share price stability

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Consensus EPS estimates fall by 23%

Independent Director recently bought US$1.0m worth of stock

Independent Director recently bought US$999k worth of stock

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $230.000037 million.

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Now 21% overvalued after recent price rise

Biohaven Ltd., Annual General Meeting, Apr 30, 2024

Now 21% overvalued after recent price rise

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

New major risk - Financial position

Director exercised options and sold US$460k worth of stock

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Price target increased by 11% to US$33.17

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Price target increased by 7.8% to US$30.00

Price target increased by 7.4% to US$29.00

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Independent Director recently bought US$402k worth of stock

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Biohaven Ltd. Announces Positive Data from its Exploratory Electroencephalogram Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

Independent Director recently bought US$922k worth of stock

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Independent Director recently bought US$2.0m worth of stock

New minor risk - Share price stability

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: A Promising Investment In Innovative Neurological Therapies

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

High number of new and inexperienced directors

Biohaven Ltd: Assessing The Spinoff

Biohaven Non-GAAP EPS of -$1.25

Chairman & CEO recently bought US$2.1m worth of stock

Biohaven Ltd. Advances Development of the MoDE Platform Technology Licensed From Yale University

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti